NCT07655180
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
Recruiting
PHASE3Ages 18–49InterventionalPreventionInvivyd, Inc.
~210 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:COVID-19 mRNA vaccineVYD2311Placebo (Normal Saline)
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through day 6
Measured over Through 6 days after dose
+1 more outcome measured
Conditions
NCT07655180
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Invivyd Investigative Site
Overland Park, Kansasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through day 6Through 6 days after dose
- Assessment of systemic reactions solicited via e-diary through day 6Through 6 days after dose
To compare the systemic reaction of VYD2311 (study drug) with a COVID-19 vaccine when administered alone or concurrently in healthy adults. E-diaries will solicit participant reported systemic reactions including vomiting, fever, diarrhea, headache, fatigue, chills, myalgia, and arthralgia.